SG11202012159TA - Sulfonylurea compounds as inhibitors of interleukin-1 activity - Google Patents
Sulfonylurea compounds as inhibitors of interleukin-1 activityInfo
- Publication number
- SG11202012159TA SG11202012159TA SG11202012159TA SG11202012159TA SG11202012159TA SG 11202012159T A SG11202012159T A SG 11202012159TA SG 11202012159T A SG11202012159T A SG 11202012159TA SG 11202012159T A SG11202012159T A SG 11202012159TA SG 11202012159T A SG11202012159T A SG 11202012159TA
- Authority
- SG
- Singapore
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonylurea compounds
- sulfonylurea
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012159TA true SG11202012159TA (en) | 2021-01-28 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012159TA SG11202012159TA (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (https=) |
| EP (1) | EP3823726A1 (https=) |
| JP (1) | JP7411631B2 (https=) |
| KR (1) | KR20210034588A (https=) |
| CN (1) | CN112437683A (https=) |
| AR (1) | AR117617A1 (https=) |
| AU (1) | AU2019305095A1 (https=) |
| BR (1) | BR112021001012A2 (https=) |
| CA (1) | CA3104199A1 (https=) |
| CL (1) | CL2021000152A1 (https=) |
| CO (1) | CO2021000817A2 (https=) |
| CR (1) | CR20210024A (https=) |
| IL (1) | IL280139A (https=) |
| MA (1) | MA53170A (https=) |
| MX (1) | MX2021000660A (https=) |
| PE (1) | PE20211049A1 (https=) |
| PH (1) | PH12020552155A1 (https=) |
| SG (1) | SG11202012159TA (https=) |
| TW (1) | TW202019937A (https=) |
| WO (1) | WO2020018970A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| AU2021291065B2 (en) * | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| WO2023158824A1 (en) * | 2022-02-21 | 2023-08-24 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| PT1270565E (pt) | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| JP2005510542A (ja) | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| ES2600355T3 (es) * | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11339136B2 (en) | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP2020531435A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| EP3668601A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| US20210122739A1 (en) | 2017-08-15 | 2021-04-29 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| AU2019299444A1 (en) | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| TWI811400B (zh) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko not_active Withdrawn
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en not_active Ceased
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es not_active Application Discontinuation
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021530536A (ja) | 2021-11-11 |
| TW202019937A (zh) | 2020-06-01 |
| IL280139A (en) | 2021-03-01 |
| PE20211049A1 (es) | 2021-06-04 |
| CL2021000152A1 (es) | 2021-07-09 |
| CR20210024A (es) | 2021-02-22 |
| US20210261568A1 (en) | 2021-08-26 |
| MX2021000660A (es) | 2021-03-25 |
| KR20210034588A (ko) | 2021-03-30 |
| CN112437683A (zh) | 2021-03-02 |
| BR112021001012A2 (pt) | 2021-04-20 |
| US11560391B2 (en) | 2023-01-24 |
| AU2019305095A1 (en) | 2020-12-17 |
| AR117617A1 (es) | 2021-08-18 |
| CA3104199A1 (en) | 2020-01-23 |
| EP3823726A1 (en) | 2021-05-26 |
| MA53170A (fr) | 2021-05-26 |
| JP7411631B2 (ja) | 2024-01-11 |
| WO2020018970A1 (en) | 2020-01-23 |
| PH12020552155A1 (en) | 2021-07-05 |
| CO2021000817A2 (es) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280139A (en) | Sulphonylureas as inhibitors of interleukin-1 activity | |
| IL279256A (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| IL267961A (en) | Chemical compounds such as interleukin-1 activity inhibitors | |
| DK3873903T3 (da) | Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere | |
| IL290929A (en) | Transmuted cyanopyrrolidines with activity as usp30 inhibitors | |
| DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
| DK3684767T3 (da) | Heterocykliske forbindelser som pad-inhibitorer | |
| EP3268006A4 (en) | Pyrrolotriazine inhibitors of irak4 activity | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| EP3268004A4 (en) | Pyrrolopyridazine inhibitors of irak4 activity | |
| EP3267996A4 (en) | Pyrazolopyrimidine inhibitors of irak4 activity | |
| IL287717A (en) | Pyrrolopyridines are converted as jak inhibitors | |
| DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
| EP3947373C0 (en) | BICYCLIC HPK1 INHIBITORS | |
| DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
| ZA202106766B (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| DK3681885T3 (da) | Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer | |
| IL276312A (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| IL289023A (en) | Bicyclic heterocyclic compounds as inhibitors of bcdin3d activity | |
| PL3826983T3 (pl) | Zastosowanie podstawionych 2-tiazolin jako inhibitorów nitryfikacji | |
| IL263356A (en) | A crystalline form of a compound that suppresses protein kinase activity, and its application | |
| PL3424930T3 (pl) | Kryształ związku wykazującego aktywność hamującą JAK | |
| GB201810746D0 (en) | Use of sclerostin antagonist | |
| ZA202105399B (en) | Use of spiropidion | |
| EP3865129A4 (en) | INHIBITORS OF TRPV4 ACTIVITY |